General Dynamics Corporation vs BIO-TECHNE Corp — how do they compare? General Dynamics Corporation trades at $393.47 (market cap $107.13B), while BIO-TECHNE Corp trades at $72.03 (market cap $11.24B). The key difference: General Dynamics Corporation is far larger — about 9.5× BIO-TECHNE Corp's market cap, and General Dynamics Corporation pays the higher dividend (1.61%). Which is the better fit depends on your goals.
| GD | TECH | |
|---|---|---|
Market Cap | $107.13B | $11.24B |
Sector | Industrials | Health |
52-Week High | $395.97 | $72.29 |
52-Week Low | $312.53 | $43.31 |
Enterprise Value | $112.28B | $11.32B |
Dividend Yield | 1.61% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $392.05, up 1.33% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $4.24 versus $3.96 expected, with revenue growth across all segments. A $76.6 billion Navy contract awarded in July 2026 bolsters its backlog to $136.5 billion, providing visibility for future growth.
The stock offers upside to the $427.40 consensus price target, driven by defense spending tailwinds and operational execution. Risks include valuation at a 23.91 P/E and potential contract execution delays. Analyst sentiment is positive with 57% buy ratings, but overbought RSI levels near-term may limit gains.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →